PATIENTS SOUGHT FOR EVALUATION OF MANY PROMISING NEW TREATMENTS
Patients with Parkinson's disease are currently being sought by the
Experimental Therapeutics Branch (ETB) of the National Institute of
Neurological Disorders and Stroke (NINDS) for many clinical studies at the
NIH campus in Bethesda, Maryland.
OPC 14117 is a promising new drug that may slow the progression of the
difficulties associated with Parkinson's disease. This outpatient trial
involves 9 visits over a period of 24 months. All will receive a thorough
medical and neurological evaluation. Candidates should have mild to
moderate difficulties, be between 18 and 79 years of age, and in good
general health. There is no charge to participate, and in some instances
compensation and transportation may be provided.
We are also seeking patients for other studies:
* For patients with motor fluctuations, dyskinesias and/or freezing, we
have a study of dextromethorphan, which involves weekly visits to the day
hospital for up to 12 weeks.
* Postmenopausal females are needed for a study of the effect of estrogen
on parkinsonian symptoms and the response to levodopa. This study requires
two brief inpatient as well as outpatient visits over a one month period.
Healthy, nonsmoking women with no personal or strong family history of
breast or uterine cancer are needed.
There is no charge to participate in any of the above studies. To apply,
please have your neurologist or family doctor mail or fax pertinent medical
records (and MRI results, if available) to:
Thomas N. Chase, MD
NIH/NINDS/ETB
Building 10, Room 5C-103
10 CENTER DR MSC 1406
BETHESDA, MD 20892-1406
Fax Number: 301- 496-6609
For additional information, please contact Marge Gillespie, R.N. or Susan
Kastris, R.N. at 1-800-362-3479 or 301-496-4604, or e-mail Michael C.
Tierney at [log in to unmask]
